Background: Elevated pregnancy-associated plasma protein A (PAPP-A) levels are associated with increased risk of death in ischaemic heart disease as well as in haemodialysis patients. Previous research indicates that the prognostic value of PAPP-A may be stronger in patients with concomitant diabetes mellitus or signs of inflammation. We studied the association between PAPP-A and outcomes in prevalent haemodialysis patients and hypothesized that diabetes mellitus and inflammation status act as effect modifiers. Materials and Methods: Circulating PAPP-A levels were quantified using ELISA. Cox proportional hazards and quantile regression models were used for associations between PAPP-A and mortality. PAPP-A levels were log-transformed for Normality. Results: During 60-month follow-up, 37 (40%) of the 92 participants died.
| INTRODUCTION
Disturbances in the growth hormone (GH) axis are associated with cardiovascular disease (CVD) and with mortality in patients treated with haemodialysis (HD). 1 Pregnancyassociated plasma protein A (PAPP-A) influences GH action through releasing insulin-like growth factor (IGF-1), the main mediator of GH, from IGF-1 binding protein 4 and thereby making IGF-1 available to its receptor. [2] [3] [4] [5] An IGFBP-5 protease named PAPP-A2 has also been identified. 6 The type of PAPP-A discussed and investigated in this study is PAPP-A1. It should also be noted that in pregnancy, plasma levels of PAPP-A are markedly elevated and therefore more readily detected than in nonpregnant individuals. 7 Pregnancy-associated plasma protein A has been evaluated as a prognostic biomarker in CVD and elevated plasma levels predict increased risk of death in chronic stable angina pectoris and acute coronary syndromes 8 as well as in haemodialysis (HD) patients. 5, [9] [10] [11] The largest study to date of PAPP-A in HD included only patients with diabetes mellitus (DM), 10 and recently we found that DM and inflammation modulated the association between PAPP-A levels and mortality in incident HD patients, with the prognostic impact of PAPP-A appearing stronger in those with DM or signs of inflammation. 12 In this study, we aimed to investigate the association between circulating PAPP-A and cardiovascular and total mortality in prevalent HD patients and hypothesized that DM and inflammation status act as effect modifiers of these associations.
We also attempted to replicate a previously reported 12 novel association between PAPP-A and tumour necrosis factor (TNF) and correlations to CRP and IL-6. 
| MATERIALS AND METHODS
We measured PAPP-A in 92 stored BioBank samples from a larger cohort (N = 228) of prevalent HD patients described previously. 14, 15 Briefly, patients in dialysis treatment for ≥3 months were recruited from October 2003 through March 2004 from 6 dialysis units in the Stockholm-Uppsala (Sweden) region. The Medical Ethics Committee at Karolinska University Hospital and Uppsala University approved the study protocol and participants gave informed consent. Venous blood samples were drawn and stored at À70°C if not analysed immediately. Concentration of high-sensitivity C-reactive protein (CRP) was determined using routine methods at the Department of Clinical Chemistry at Karolinska University Hospital (Huddinge, Sweden). PAPP-A was assayed using an ELISA (R&D Systems, Minneapolis, USA) with intra-assay coefficient of variation of 5.8% at 5.49 ng/mL and average % of expected at 92%-102% (range 90%-104%) for dilutions of 1:2-1:16. IL-6, and TNF were analysed on an Immulite Automatic Immunoassay Analyzer (DPC, Los Angeles, CA) according to the instructions of the manufacturer.
Comorbid conditions were recorded at baseline. Definition of CVD was based on ICD-10 (10th revision of the International Statistical Classification of Diseases and Related Health Problems) codes and baseline CVD diagnoses included: Myocardial infarction (I21-I23), heart failure (I50, I42, I11), peripheral vascular disease (I70-I73), ischaemic stroke (I63), unspecified stroke (I64); hemorrhagic stroke (I60-I62) and the presence of coronary angioplasty implant and graft (Z95.5).
Diabetes mellitus included both type 1 and type 2 DM. Patients were followed until 5 years after inclusion and survival time censored at renal transplantation or death.
Causes of death were retrieved from death certificates. CV mortality was defined as death due to coronary heart disease, sudden death, stroke or complicated peripheral vascular disease.
| Statistical analysis
Associations between PAPP-A, and cardiovascular and total mortality were evaluated using Cox proportional hazards regression. PAPP-A was normalized using natural logarithm transform and standardized. Laplace regression was used to calculate the time until 25% mortality, 16 with bootstrapping for CIs. Covariable selection was based on review of previous research. Adjustment was made in three steps. First, a minimally adjusted model including only age and sex as confounders was specified. Then, a model with as complete adjustment for potential confounders as possible, taking into account the relatively low number of expected events, was constructed. Finally, to indicate whether PAPP-A would add to established cardiovascular risk markers, the latter were added as covariables.
Based on previous findings, we a-priori decided to perform multiplicative interaction analyses in order to assess whether there was any effect modification of the association between PAPP-A and outcome by diabetes or inflammation status and to further investigate statistically significant interactions in stratified analysis. We also examined associations of PAPP-A and TNF, CRP, and IL-6 with baseline characteristics using Spearman's rank correlation.
Descriptive data are presented in Table 1 as mean (SD) or median (IQR) if continuous and % if categorical. Significance level was set at P < .05 and statistical software STATA 12 (Stata corp, College Station, TX) used in all analyses. Ratios were rounded to three significant digits and other numeric values to 2 significant digits, trailing zeroes omitted.
| RESULTS
Mean age was 62 (SD 14) years, and 61% of participants were male. About 24% had DM, 66% were previous or current smokers and 60% had prevalent CVD. Additional baseline characteristics are presented in Table 1 . All participants were followed for a minimum of 5 years, and survival time was truncated at 60 months for a total time at risk of 366 years.
During follow-up, 37 (40%) patients died. Higher PAPP-A was associated with increased risk of mortality in unadjusted analysis (per SD of log-transformed PAPP-A HR = 1.4, 95% CI 1-1.9, P = .03).
Multivariable adjusted models of survival are presented in Table 2 . PAPP-A was associated with survival when adjusted for age and sex, and this association was strengthened when DM, BMI and CRP were also included. When additionally adjusting for dialysis vintage and cardiovascular risk factors, the association between PAPP-A and survival remained statistically significant.
To test for effect modification from DM and inflammatory status, we constructed Cox proportional hazards models with corresponding interaction terms. The interaction between PAPP-A levels and DM (Table 3 ) was positive and statistically significant, indicating that the risk associated with higher PAPP-A levels increased when DM was also present. There appeared to be no effect modification by inflammatory status as assessed by CRP (Table 4) .
The cohort was then stratified by diabetes status, and the resulting survival analysis is presented in Table 5 . Although a minority of participants (n = 22) had DM, PAPP-A predicted survival in this subgroup but not in those without DM. Notably, the precision of estimates was low due to the limited number of individuals in each strata.
In a quantile regression model adjusted for age and sex, 1 standard deviation higher level of PAPP-A was associated with 22 months shorter estimated time until 25% of the patients died (95% CI À35 to À9.1) months.
We were not able to replicate any association between PAPP-A and inflammatory markers TNF (Spearman's rho = À0.0294, P-value = .78), CRP (rho = À0.016, Pvalue = .88) or IL-6 (rho = À0.025, P-value = .81).
Death due to cardiovascular causes was recorded in 16 (17%) cases, and risk of cardiovascular mortality was calculated using Cox proportional hazards regression. PAPP-A levels were not associated with cardiovascular death in unadjusted (HR 1.34, 95% CI 0.846-2.13, P = .21) analysis or when adjusted for age and sex (HR 1.31, 95% CI 0.835-2.06, P = .24).
| DISCUSSION
Our chief finding was that elevated PAPP-A levels associated with increased risk of death in diabetic HD patients, while in nondiabetics the prognostic utility of PAPP-A was less clear.
There is some prior evidence that PAPP-A may have a causative role in the pathogenesis of CVD and thereby contribute to increased mortality. In experimental rodent models, reduced PAPP-A activity has been associated with increased lifespan, diminished vascular cell proliferation in response to injury, reduced plaque area and less luminal occlusion in atherosclerosis. 17 Conversely, increased PAPP-A activity has been associated with proliferation of vascular smooth muscle cells and increased atherosclerosis in rodents. 18 In HD patients, 1 of 2 investigated PAPP-A single nucleotide polymorphisms predicted all-cause mortality and (in unadjusted analysis) cardiovascular mortality. 19 Although this supports a causative role of PAPP-A in the process of atherosclerosis, elevated plasma levels of PAPP-A may instead represent up-regulation of tissue expression in response to tissue injury or inflammation, and increased escape of normally membrane-bound, noncomplexed PAPP-A into the circulation, 7 rather than being a driving force in the atherosclerotic process. Thus, the association between plasma PAPP-A and outcomes do not necessarily indicate a causative role of PAPP-A in CVD. Indeed, Kalausova et al 5 reported that PAPP-A was associated to death due to infection and not to cardiovascular death.
Our results add to the limited number of previous studies on PAPP-A in prevalent HD patients, showing that PAPP-A levels are associated to all-cause mortality in cohorts including both diabetic and nondiabetic patients. 5, 9, 11 In the largest study to date on PAPP-A as a prognostic marker in HD, only patients with DM were included 10 and recently we found that in incident HD patients, the prognostic impact of PAPP-A appeared stronger in those with DM.
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The present study provides novel evidence that effect modification from DM can be observed also in prevalent HD patients. This distinction is important due to the high early mortality after dialysis initiation, 20 which contributes to differences in characteristics between incident and prevalent HD patients. It should especially be noted that the proportion of patients with DM is likely to be lower in prevalent than incident HD (due to DM being a risk factor for mortality) and that results from incident cohorts are not automatically valid in prevalent ones and vice versa. Importantly, there may also be differences in types of CVD mortality between incident and prevalent HD patients.
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Although PAPP-A is linked to cardiovascular disease, it is not clear whether the predictive utility of PAPP-A in HD is due to association with cardiovascular mortality. In a previous study by Kalousova et al 5 PAPP-A predicted allcause mortality and death due to infection but not cardiovascular mortality and in a subsequent study an association with sudden death, stroke and death due to infection was found, but there was no statistically significant association with risk of myocardial infarction. 10 In accordance, we found no association between PAPP-A levels and cardiovascular mortality, although the limited power of this analysis should be emphasized. In contrast to previous findings, 8, 12 we detected no interaction between PAPP-A and CRP. Differences between prevalent and incident HD patients and a limited sample size are potential explanations for these differences in results. Important limitations apply to these findings. Low statistical power due to a relatively small number of participants restricted the number of covariates that could be included in the statistical models, in turn increasing the likelihood of residual confounding. Adding to this, in spite of using an ELISA for determining PAPP-A with high sensitivity, a large proportion of PAPP-A values were below lowest standard, leading to decreased precision of measurements and therefore reduction in statistical power. It should be noted that limited statistical power also increases the risk of type I and type II error. However, the relatively low number of participants was to some extent balanced by a high event rate and results in the fully adjusted models were consistent with ones including a smaller number of covariates. Further, characterization of CVD was based on medical history and did not systematically utilize diagnostic testing, leading to risk of misclassification. Also, our definition of DM included both type 1 and type 2 DM, which precludes differentiation between these 2 conditions. The post hoc analysis of existing cohort data and stored samples should also be acknowledged and may contribute to publication bias. To ameliorate this, the specific hypotheses and statistical models were stipulated before analysis of results. Nevertheless, our results align with previous evidence 10, 12 of DM as an effect modifier on the association between PAPP-A and survival in incident HD patients. We conclude that there is prior evidence that PAPP-A levels predict outcomes in prevalent HD patients with DM but that it is less clear whether this is also true in nondiabetic HD patients. We have previously shown that the association between PAPP-A and mortality in incident HD patients is affected by diabetes status, and the present study provides novel evidence that effect modification from DM can be observed also in prevalent HD patients. This implies that results concerning the association of PAPP-A to survival that are based on patients with DM may not be generalizeable to HD patients without DM.
